Old Web
English
Sign In
Acemap
>
authorDetail
>
Kathleen M. Weisel
Kathleen M. Weisel
GlaxoSmithKline
Pharmacodynamics
Medicine
Inflammation
Placebo
Pharmacokinetics
3
Papers
19
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
A randomized, placebo-controlled experimental medicine study of RIPK1 inhibitor GSK2982772 in patients with moderate to severe rheumatoid arthritis.
2021
Arthritis Research & Therapy
Kathleen M. Weisel
Scott B. Berger
Katie Thorn
Peter C. Taylor
Charles Peterfy
Hilary Siddall
Debra J. Tompson
Susanne Wang
Emilia Quattrocchi
Susan W. Burriss
Jochen Walter
Paul P. Tak
Show All
Source
Cite
Save
Citations (7)
Response to inhibition of receptor-interacting protein kinase 1 (RIPK1) in active plaque psoriasis: a randomized placebo-controlled study.
2020
Clinical Pharmacology & Therapeutics
Kathleen M. Weisel
Scott B. Berger
Kim Papp
Catherine Maari
James G. Krueger
Nicola Scott
Debra J. Tompson
Susanne Wang
Monica Simeoni
John Bertin
Paul-Peter Tak
Show All
Source
Cite
Save
Citations (12)
Amides hétérocycliques utilisés comme inhibiteurs de la rip1 kinase en tant que médicaments
2015
Scott B. Berger
Peter J. Gough
Kathleen M. Weisel
Show All
Source
Cite
Save
Citations (0)
1
map